Albendazole is a benzimidazole carbamate anthelmintic. Albendazole’s anthelmintic activity is considered to be dependent on the inhibition or destruction of cytoplasmic microtubules in the worm’s intestinal or absorptive cells. Inhibition of glucose uptake and depletion of glycogen stores follow as do other inhibitory effects leading to death of the worm within several days.
Albendazole is poorly absorbed from the gastro-intestinal tract, but rapidly undergoes extensive first-pass metabolism. The principal metabolite Albendazole Sulfoxide has anthelmintic activity and a plasma half-life of about 8.5 hours. Albendazole Sulfoxide is widely distributed throughout the body including into the bile and the cerebrospinal fluid. It is approximately 70% bound to plasma protein. Albendazole Sulfoxide is eliminated in the bile; only a small amount appears to be excreted in the urine.
Albendazole is used in the treatment of cestode infections cysticercosis and echinococcosis (hydatid disease). It is also used in the treatment of single and mixed intestinal nematode infections including ascariasis, enterobiasis, hookworm, strongyloidiasis and trichuriasis.
DOSAGE AND ADMINISTRATION:
In the treatment of single or mixed intestinal nematode infection: The usual dose for adults and children aged 2 years or over with Roundworm (ascariasis), Hookworm, Pinworm (enterobiasis) and Whipworm (trichuriasis) is 400mg as a single dose. In Pinworm (enterobiasis) the dose may be repeated in one to four weeks. In strongyloidiasis, 400mg is given once or twice daily for three consecutive days, this may be repeated after three weeks if necessary.